Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Muvalaplin (LY3473329) | Lp (a) Inhibitor | MedChemExpress
Muvalaplin as an Inhibitor of Lipoprotein(a) Formation | JAMA
Muvalaplin | TargetMol
Muvalaplin tetrahydrochloride | TargetMol
Muvalaplin | Drug Information, Uses, Side Effects, Chemistry ...
Oral Muvalaplin effectively lowers lipoprotein (a) with no serious ...
Lp(α)小分子抑制剂- Muvalaplin (1) | 化学空间 Chem-Station
Muvalaplin Shows Promise in Lowering LP (A) Levels in Clinical TR | PDF ...
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical ...
Muvalaplin as an Inhibitor of Lipoprotein(a) Formation | Metabolic ...
Novel Oral Drug Muvalaplin Lowers Lipoprotein (a) Levels: Clinical ...
Muvalaplin shows promise for lowering Lp(a) levels in clinical trials ...
Muvalaplin Significantly Lowers Lipoprotein(a) in Adults With High Risk ...
Muvalaplin Shows Promising Results in Lowering Lipoprotein(a) Levels
Muvalaplin | C42H54N4O6 | CID 155369486 - PubChem
KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial | AJMC
Muvalaplin Aces Phase 2 Lp(a) Test - Cardiac Wire
Muvalaplin : nouvel inhibiteur de la lp(a) par voie orale
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in ...
Muvalaplin Found to Significantly Lower Lipoprotein(a) Levels, Offering ...
KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial
Phase 2 Data Support Muvalaplin for Lowering Lp(a), with Stephen ...
Oral Muvalaplin for Lowering of Lipoprotein(a) - American College of ...
Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in ...
Full article: Potential of muvalaplin as a lipoprotein(a) inhibitor
Muvalaplin|LY3473329——药研档案
経口小分子Lipoprotein(a)（Lp(a)）阻害薬Muvalaplin｜Makisey
Muvalaplin(LY3473329) | CAS 2565656-70-2 | Selleck
Muvalaplin, a small-molecule lipoprotein(a) inhibitor, produced ...
ESC 365 - Muvalaplin, a Potent Small Molecule Inhibitor of Lipoprotein(a)
Future Lp(a) Treatment Options
JAMA | 降Lp(a)疗法最新进展，小分子口服药Muvalaplin降幅超85% – 伯科生物
Oral Lp(a) inhibitor, muvalaplin, well tolerated, lowers Lp(a) by 70-85 ...
Muvalaplin: Il Farmaco Orale per Combattere la Lp(a)
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a ...
ランダムトライアル：Muvalaplin, Lp(a) 経口小分子Lp(a) 合成阻害剤｜Makisey
Oral muvalaplin, reduced levels of lipoprotein(a), or Lp(a), by nearly ...
Muvalaplin: Oraler Inhibitor senkt Lipoprotein(a) in Phase-1-Studie ...
Muvalaplin, a novel oral medication, safely and effectively lowers high ...
Muvalaplin: first clinical data for an oral Lp(a)-lowering therapy - R3i
穆伐普林(Muvalaplin) - 药物靶点：Lp(a)_在研适应症：外周动脉疾病，动脉粥样硬化，冠状动脉疾病_专利_临床_研发
Eli Lilly's Muvalaplin: 85% Lp(a) Reduction
JAMA：世界首个口服药，心脏病标志物水平降低65%-MedSci.cn
KRAKEN Trial Highlights Muvalaplin’s Efficacy, Safety in Reducing ...
Eli Lilly Announces Positive Phase 2 Results for Muvalaplin, Oral ...
Muvalaplin, an Oral Agent for Lowering Lp(a), Shows Promise in Phase 1 ...
科研助攻 | “隐形杀手“-- 血脂异常：有哪些干预靶点？ | MedChemExpress (MCE)_olpasiran-CSDN博客
Neues orales Medikament senkt in Studie Lipoprotein(a)
lipoprotein (a) drug, Muvalaplin, clears phase II clinical trials ...
Muvalaplin: Zukunftspotenzial bei erhöhten Lipoprotein(a)-Werten? | D•A ...
Muvalaplin, an Oral Lp(a)-Lowering Agent, Shows Promise in Phase 2 ...
First Drug Shown to Lower Lp(a) in Heart Attack Prevention (Muvalaplin ...
研究进展|评估Muvalaplin降低脂蛋白(a)的临床进展情况 - 知乎
#muvalaplin #ly3473329 #lp #lipoprotein #pelacarsen #olpasiran… | Min W.
.png)
